XOMA Royalty Corporation (XOMA)

Market Cap	249.16M
Revenue (ttm)	28.49M
Net Income (ttm)	-19.29M
Shares Out	11.98M
EPS (ttm)	-1.65
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	17,924
Open	20.36
Previous Close	20.28
Day's Range	20.30 - 21.40
52-Week Range	18.35 - 35.00
Beta	1.00
Analysts	Strong Buy
Price Target	72.00 (+246.15%)
Earnings Date	May 8, 2025

About XOMA

XOMA Royalty Corporation operates as a biotech royalty aggregator in the United States and the Asia Pacific. It has a portfolio of economic rights to future potential milestone and royalty payments associated with partnered commercial and pre-commercial therapeutic candidates. The company also focuses on early to mid-stage clinical assets primarily in Phase 1 and 2 with commercial sales potential that are licensed to partners; and acquires milestone and royalty revenue streams on late-stage clinical or commercial assets. It has a portfolio with...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1981
• Employees: 13
• Stock Exchange: NASDAQ
• Ticker Symbol: XOMA
• Website: https://www.xoma.com

Financial Performance

In 2024, XOMA Royalty's revenue was $28.49 million, an increase of 498.72% compared to the previous year's $4.76 million. Losses were -$19.29 million, -58.33% less than in 2023.

Analyst Forecast

According to 2 analysts, the average rating for XOMA stock is "Strong Buy." The 12-month stock price forecast is $72.0, which is an increase of 246.15% from the latest price.

Price Target

$72.0

(246.15% upside)

Analyst Consensus: Strong Buy